Watson Bio announced that it achieved a net profit of 45.17 million yuan in the third quarter, down 87.92% year-on-year; in the first three quarters, it achieved a net profit of 360 million yuan, down 16.33% year-on-year.
In the past 90 days, a total of 7 institutions have given ratings, 5 buy ratings and 2 overweight ratings; the target average price of institutions in the past 90 days has been 90.0; the net inflow of financing in the past 3 months has increased by 1.226 billion yuan, and the balance of financing has increased; and the net outflow of margin has been 108 million, and the balance of margin has decreased. The Securities Star Valuation Analysis Tool shows that Watson Bio (300142) has a good company rating of 3 stars, a good price rating of 1.5 stars, and a valuation composite rating of 2 stars.
The chairman of the company is Li Yunchun. Mr. Li Yunchun: Born in December 1962, Chinese nationality, bachelor degree, Mr. Li Yunchun has nearly 30 years of technical background and enterprise management experience in the medical biological products industry, and was elected as the fifth outstanding builder of socialism with Chinese characteristics in the non-public economic figures of Yunnan Province in 2019. He has served as a director, chairman and president of the company. He is currently a director and chairman of the board of directors of the company.
This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if there are any problems in the text, please contact us.
![Explosive melon, the richest man quietly built a warehouse Watson creature, pay close attention to the melon of the possible more preemptive Watson creatures a brain hole[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)